RU2018102205A - Супрессия опухолей с использованием полученных из плаценты человека промежуточных естественных киллерных клеток и иммуномодулирующих соединений - Google Patents
Супрессия опухолей с использованием полученных из плаценты человека промежуточных естественных киллерных клеток и иммуномодулирующих соединений Download PDFInfo
- Publication number
- RU2018102205A RU2018102205A RU2018102205A RU2018102205A RU2018102205A RU 2018102205 A RU2018102205 A RU 2018102205A RU 2018102205 A RU2018102205 A RU 2018102205A RU 2018102205 A RU2018102205 A RU 2018102205A RU 2018102205 A RU2018102205 A RU 2018102205A
- Authority
- RU
- Russia
- Prior art keywords
- lymphoma
- cell
- leukemia
- acute
- cell lymphoma
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims 5
- 210000002826 placenta Anatomy 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
- 230000005760 tumorsuppression Effects 0.000 title 1
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 201000006845 reticulosarcoma Diseases 0.000 claims 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000035462 Biphenotypic Acute Leukemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 208000036677 acute biphenotypic leukemia Diseases 0.000 claims 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 claims 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000006778 chronic monocytic leukemia Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000024386 fungal infectious disease Diseases 0.000 claims 1
- 229940084434 fungoid Drugs 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000007282 lymphomatoid papulosis Diseases 0.000 claims 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002992 thymic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (1)
- Способ лечения индивидуума, страдающего злокачественной опухолью, предусматривающий введение указанному индивидууму выделенных естественных киллерных клеток, содержащих выделенные CD56+,CD16- промежуточные естественные киллерные клетки плаценты, где указанная злокачественная опухоль представляет собой острый промиелоцитарный лейкоз, острый миелобластный лейкоз, острый мегакариобластный лейкоз, острый лимфобластный лейкоз предшественников B-клеток, острый лимфобластный лейкоз предшественников T-клеток, лейкоз Беркитта (лимфому Беркитта), острый бифенотипический лейкоз, хронический моноцитарный лейкоз, хронический лимфоцитарный лейкоз (CLL)/мелколимфоцитарную лимфому, B-клеточный пролимфоцитарный лейкоз; волосатоклеточную лимфому; T-клеточный пролимфоцитарный лейкоз, лимфоплазматическую лимфому, макроглобулинемию Вальденстрема, лимфому маргинальной зоны селезенки, плазмацитому, болезнь накопления моноклональных иммуноглобулинов или заболевание тяжелых цепей, экстранодальную B-клеточную лимфому маргинальной зоны (MALT лимфому), нодальную B-клеточную лимфому маргинальной зоны (NMZL), фолликулярную лимфому, лимфому из клеток мантийной зоны, диффузную B-крупноклеточную лимфому, медиастинальную (тимическую) B-крупноклеточную лимфому, внутрисосудистую B-крупноклеточную лимфому, первичную выпотную лимфому, T-клеточный крупногранулярный лимфоцитарный лейкоз, агрессивный NK-клеточный лейкоз, экстранодальную NK/T-клеточную лимфому назального типа, T-клеточную лимфому энтеропатического типа, печеночно-селезеночную T-клеточную лимфому, бластную NK-клеточную лимфому, фунгоидный микоз (синдром Сезари), первичное кожное лимфопролиферативное нарушение CD30-положительных T-клеток, первичную кожную анапластическую крупноклеточную лимфому, лимфоматоидный папулез, ангиоиммунобластную T-клеточную лимфому, неспецифическую периферическую T-клеточную лимфому, анапластическую крупноклеточную лимфому, лимфому Ходжкина, нодулярную лимфому Ходжкина с лимфоидным преобладанием, ретинобластому или колоректальную карциному.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16344909P | 2009-03-25 | 2009-03-25 | |
| US61/163,449 | 2009-03-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011142911A Division RU2642988C2 (ru) | 2009-03-25 | 2010-03-26 | Супрессия опухолей с использованием полученных из плаценты человека промежуточных естественных киллерных клеток и иммуномодулирующих соединений |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018102205A true RU2018102205A (ru) | 2019-02-22 |
| RU2018102205A3 RU2018102205A3 (ru) | 2019-02-22 |
| RU2742171C2 RU2742171C2 (ru) | 2021-02-02 |
Family
ID=42315196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018102205A RU2742171C2 (ru) | 2009-03-25 | 2010-03-26 | Супрессия опухолей с использованием полученных из плаценты человека промежуточных естественных киллерных клеток и иммуномодулирующих соединений |
| RU2011142911A RU2642988C2 (ru) | 2009-03-25 | 2010-03-26 | Супрессия опухолей с использованием полученных из плаценты человека промежуточных естественных киллерных клеток и иммуномодулирующих соединений |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011142911A RU2642988C2 (ru) | 2009-03-25 | 2010-03-26 | Супрессия опухолей с использованием полученных из плаценты человека промежуточных естественных киллерных клеток и иммуномодулирующих соединений |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP2411506B1 (ru) |
| AU (1) | AU2010229711B2 (ru) |
| CA (2) | CA2756594C (ru) |
| DK (1) | DK2411506T3 (ru) |
| ES (1) | ES2713524T3 (ru) |
| IL (2) | IL215228A (ru) |
| NZ (1) | NZ595440A (ru) |
| PL (1) | PL2411506T3 (ru) |
| PT (1) | PT2411506T (ru) |
| RU (2) | RU2742171C2 (ru) |
| WO (1) | WO2010111631A1 (ru) |
| ZA (2) | ZA201106982B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2203176T1 (sl) | 2007-09-28 | 2015-04-30 | Anthrogenesis Corporation | Tumorska supresija z uporabo humanega perfuzata placente in intermediarnih naravnih celic ubijalk, pridobljenih iz humane placente |
| KR20210063457A (ko) | 2010-07-13 | 2021-06-01 | 안트로제네시스 코포레이션 | 천연 킬러 세포의 생성 방법 |
| EP2953635A4 (en) * | 2013-02-05 | 2016-10-26 | Anthrogenesis Corp | NATURAL KILLER CELLS FROM PLAZENTA |
| US9931332B2 (en) * | 2014-07-30 | 2018-04-03 | University Of Southern California | Compositions and methods for treating primary effusion lymphoma |
| EP4034567A4 (en) * | 2019-09-23 | 2023-07-05 | Neonc Technologies, Inc. | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES |
| US20220000919A1 (en) * | 2020-01-29 | 2022-01-06 | Celularity Inc. | Placental derived natural killer cells for treatment of coronavirus infections |
| EP4180049A1 (en) * | 2021-11-16 | 2023-05-17 | Ostravska univerzita | Therapeutic composition for cancer treatment |
| WO2024100203A1 (en) * | 2022-11-10 | 2024-05-16 | Onk Therapeutics Limited | Combined therapies using immunomodulating drugs |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US5190556A (en) | 1991-03-19 | 1993-03-02 | O.B. Tech, Inc. | Cord cutter sampler |
| US5552267A (en) | 1992-04-03 | 1996-09-03 | The Trustees Of Columbia University In The City Of New York | Solution for prolonged organ preservation |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5372581A (en) | 1993-07-21 | 1994-12-13 | Minneapolis Children's Services Corporation | Method and apparatus for placental blood collection |
| US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| ES2339425T3 (es) | 1996-07-24 | 2010-05-20 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas y -1-oxoisoindolinas sustituidas y procedimiento para reducir los niveles de tnf-alfa. |
| EP1361210B1 (en) | 1996-08-12 | 2008-12-24 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| ATE323756T1 (de) * | 1997-04-30 | 2006-05-15 | Hans Klingemann | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
| US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
| US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
| CZ299253B6 (cs) | 1998-03-16 | 2008-05-28 | Celgene Corporation | Isoindolinový derivát, jeho použití pro výrobu léciva a farmaceutická kompozice tento derivát obsahující |
| CZ20013338A3 (cs) | 1999-03-18 | 2002-03-13 | Celgene Corporation | Substituované 1-oxo-a l,3-dioxoisoindoliny a jejich pouľití ve farmaceutických prostředcích pro sníľení koncentrací zánětlivých cytokinů |
| KR100696408B1 (ko) | 1999-04-16 | 2007-03-19 | 더블유엠. 마쉬 라이스 유니버시티 | 폴리(에틸렌글리콜)과 가교결합을 이룬 폴리(프로필렌푸마레이트) |
| US6355699B1 (en) | 1999-06-30 | 2002-03-12 | Ethicon, Inc. | Process for manufacturing biomedical foams |
| JP2002045174A (ja) | 2000-07-31 | 2002-02-12 | Inst Of Physical & Chemical Res | ナチュラルキラー細胞増殖法 |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| CA2430989A1 (en) | 2000-12-06 | 2002-06-13 | Robert J. Hariri | Method of collecting placental stem cells |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| AU2002251935B2 (en) | 2001-02-14 | 2007-11-29 | Celularity Inc. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| US20030187515A1 (en) | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| CN101111234A (zh) | 2004-12-01 | 2008-01-23 | 细胞基因公司 | 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途 |
| AU2006208201A1 (en) | 2005-01-25 | 2006-08-03 | Celgene Corporation | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
| WO2007011693A2 (en) * | 2005-07-14 | 2007-01-25 | Medistem Laboratories, Inc. | Compositions of placentally-derived stem cells for the treatment of cancer |
| RU2008112221A (ru) | 2005-08-31 | 2009-10-10 | Селджин Корпорейшн (Us) | Соединения ряда изоиндолимидов, их композиции и способы применения |
| EP1789435B1 (en) * | 2005-09-12 | 2010-02-24 | Industry Foundation of Chonnam National University | A method for production of mature natural killer cell |
| KR20180105266A (ko) | 2005-12-29 | 2018-09-27 | 안트로제네시스 코포레이션 | 태반 줄기 세포 집단 |
| US9598669B2 (en) | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
| US7993918B2 (en) * | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
| AU2008216749B2 (en) * | 2007-02-12 | 2014-03-13 | Celularity Inc. | Treatment of inflammatory diseases using placental stem cells |
| SI2203176T1 (sl) * | 2007-09-28 | 2015-04-30 | Anthrogenesis Corporation | Tumorska supresija z uporabo humanega perfuzata placente in intermediarnih naravnih celic ubijalk, pridobljenih iz humane placente |
-
2010
- 2010-03-26 PL PL10722830T patent/PL2411506T3/pl unknown
- 2010-03-26 CA CA2756594A patent/CA2756594C/en active Active
- 2010-03-26 CA CA3110964A patent/CA3110964A1/en not_active Abandoned
- 2010-03-26 NZ NZ595440A patent/NZ595440A/en unknown
- 2010-03-26 DK DK10722830.6T patent/DK2411506T3/en active
- 2010-03-26 RU RU2018102205A patent/RU2742171C2/ru not_active Application Discontinuation
- 2010-03-26 EP EP10722830.6A patent/EP2411506B1/en active Active
- 2010-03-26 RU RU2011142911A patent/RU2642988C2/ru active
- 2010-03-26 ES ES10722830T patent/ES2713524T3/es active Active
- 2010-03-26 EP EP18199875.8A patent/EP3489352A1/en active Pending
- 2010-03-26 AU AU2010229711A patent/AU2010229711B2/en active Active
- 2010-03-26 WO PCT/US2010/028885 patent/WO2010111631A1/en active Application Filing
- 2010-03-26 PT PT10722830T patent/PT2411506T/pt unknown
-
2011
- 2011-09-19 IL IL215228A patent/IL215228A/en active IP Right Grant
- 2011-09-23 ZA ZA2011/06982A patent/ZA201106982B/en unknown
-
2015
- 2015-06-25 ZA ZA2015/04633A patent/ZA201504633B/en unknown
-
2016
- 2016-11-08 IL IL248842A patent/IL248842A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3489352A1 (en) | 2019-05-29 |
| ZA201504633B (en) | 2020-12-23 |
| DK2411506T3 (en) | 2019-03-04 |
| PT2411506T (pt) | 2019-03-19 |
| RU2011142911A (ru) | 2013-04-27 |
| WO2010111631A1 (en) | 2010-09-30 |
| AU2010229711B2 (en) | 2015-06-04 |
| EP2411506B1 (en) | 2018-11-07 |
| CA2756594A1 (en) | 2010-09-30 |
| CA2756594C (en) | 2021-03-23 |
| AU2010229711A1 (en) | 2011-10-27 |
| PL2411506T3 (pl) | 2019-07-31 |
| IL215228A (en) | 2016-11-30 |
| NZ595440A (en) | 2014-05-30 |
| RU2018102205A3 (ru) | 2019-02-22 |
| IL215228A0 (en) | 2011-12-29 |
| RU2642988C2 (ru) | 2018-01-29 |
| RU2742171C2 (ru) | 2021-02-02 |
| IL248842A0 (en) | 2017-01-31 |
| CA3110964A1 (en) | 2010-09-30 |
| ES2713524T3 (es) | 2019-05-22 |
| EP2411506A1 (en) | 2012-02-01 |
| ZA201106982B (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018102205A (ru) | Супрессия опухолей с использованием полученных из плаценты человека промежуточных естественных киллерных клеток и иммуномодулирующих соединений | |
| Khaled et al. | Myeloid‐derived suppressor cells in cancer: recent progress and prospects | |
| Kasamon et al. | FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and Sezary syndrome | |
| Ksienzyk et al. | IRF-1 expression is essential for natural killer cells to suppress metastasis | |
| Andersson et al. | IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer | |
| Andersson et al. | Role of CXCR3 Ligands in IL-7/IL-7Rα-Fc–Mediated Antitumor Activity in Lung Cancer | |
| RU2007140351A (ru) | Клапан, предназначенный в особенности для накладки для сбора грудного молока | |
| RU2014133069A (ru) | Транслокации r-спондина и способы с их использованием | |
| DE602004009180D1 (de) | Strömungsfeldplattengeometrien | |
| RU2008104420A (ru) | Антитела против рецептора ccr7 для лечения рака | |
| MY154819A (en) | Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia | |
| Ahmed et al. | Cutaneous Castleman's disease responds to anti–interleukin-6 treatment | |
| Sterner et al. | Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies | |
| KR20120042515A (ko) | 다공성 금속필터 | |
| AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
| SG169295A1 (en) | Fresnel lens sheet and luminaire using the same | |
| Alhaddad et al. | The molecular and cellular strategies of glioblastoma and non-small-cell lung cancer cells conferring radioresistance | |
| Hersh et al. | Effect of haematological malignancies and their treatment on host defence factors | |
| MX2014007188A (es) | Subpoblación de monocitos humanos para el tratamiento de daños al sistema nervioso central. | |
| Cengiz et al. | Frequency and risk factors for secondary malignancies in patients with mycosis fungoides | |
| Walker et al. | Bilateral auricular involvement: a rare presenting sign of chronic lymphocytic leukemia, and successful treatment with electron beam therapy | |
| Dior et al. | Hypersensitivity reaction to a mosquito bite in a patient with chronic myeloid leukemia | |
| Hunter et al. | Fifteen years of interleukin-27-discovery, advances and translation | |
| Assaf et al. | CD56 lymphoproliferative disorders of the skin: A multicenter study of the Cutaneous Lymphoma Project Group of the European Organization for Research and Treatment of Cancer (EORTC) | |
| Rojas-Dotor et al. | Effect of the monocyte locomotion inhibitory factor (MLIF) produced by E. histolityca on cytokines and chemokine receptors in T CD4+ lymphocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190916 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20200915 |